Citigroup
CRDF icon

Citigroup’s Cardiff Oncology CRDF Stock Holding History

Citigroup’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-40
Closed -$2K – 7560
2017
Q3 		$2K Sell
40
-25
-38% -$1.56K ﹤0.01% 7013
2017
Q2 		$6K Buy
+65
New +$4.19K ﹤0.01% 6681

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

Citigroup's CRDF Position: Q1 2026 in Review

Citigroup increased its Cardiff Oncology (CRDF) stake by 2,770% in Q1 2026, buying an estimated $79.8K and bringing the position to 40,266 shares worth $65.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4428.

Citigroup first reported a position in CRDF in Q2 2013 and has held it in 37 quarters since. The position peaked at $1.07M in Q1 2023. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • Citigroup held 40,266 shares of Cardiff Oncology worth $65.2K as of Q1 2026.
  • Citigroup bought 38,863 Cardiff Oncology shares in Q1 2026, an estimated $79.8K.
  • Cardiff Oncology made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4428 holding.
  • Citigroup first reported a position in Cardiff Oncology in Q2 2013 and has held it in 37 quarters since.
  • Citigroup's Cardiff Oncology position peaked at $1.07M in Q1 2023.
  • 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.